Navitoclax clinical trials
Also written ABT-263 and A-855071.0.
How each study uses navitoclax is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the navitoclax studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
37 studies that test it; most in 2009 (8)
| Year | Studies |
|---|---|
| 2006 | 1 |
| 2007 | 2 |
| 2008 | 1 |
| 2009 | 8 |
| 2010 | 4 |
| 2011 | 1 |
| 2012 | 1 |
| 2013 | 1 |
| 2014 | 1 |
| 2015 | 1 |
| 2016 | 2 |
| 2017 | 2 |
| 2018 | 1 |
| 2019 | 1 |
| 2020 | 2 |
| 2021 | 1 |
| 2022 | 4 |
| 2023 | 2 |
| 2024 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 23 · Other 14
AbbVie (11) · National Cancer Institute (NCI) (5) · AbbVie (prior sponsor, Abbott) (5) · Abbott (5) · Genentech, Inc. (2) · St. Jude Children's Research Hospital (1) · City of Hope Medical Center (1) · Jacqueline Garcia, MD (1)
Often tested with
Tested in the same studies.
Venetoclax (8) · Decitabine (3) · Ruxolitinib (2) · Antineoplastic Agents (1) · Erlotinib (1) · Irinotecan (1) · Rituximab (1) · Vistusertib (1)
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 2
Studies that test navitoclax.
- Dec 2026A Study Evaluating Safety and Tolerability, and Pharmacokinetics of Navitoclax Monotherapy and in Combination With Ruxolitinib in Participants With Myeloproliferative NeoplasmPhase 1 · AbbVie
- Mar 2027Navitoclax, Venetoclax, and Decitabine for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia Previously Treated With VenetoclaxPhase 1 · City of Hope Medical Center
Studies
Open first, then newest update. How each study uses navitoclax is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 37
- A Phase 1b-2 Trial to Assess Venetoclax and Navitoclax Consolidation and Post-transplant Maintenance in High-risk Patients With T-ALLNot yet recruitingPhase 1/2Israeli Medical AssociationNCT05054465Written as NavitoclaxHow we know
- Trametinib and Navitoclax in Treating Patients With Advanced or Metastatic Solid TumorsActive, not recruitingPhase 1/2National Cancer Institute (NCI)NCT02079740Written as NavitoclaxHow we know
- Trial Treating Relapsed Acute Lymphoblastic Leukemia With Venetoclax and NavitoclaxActive, not recruitingPhase 1/2St. Jude Children's Research HospitalNCT05192889Written as NavitoclaxHow we know
- Navitoclax, Venetoclax, and Decitabine for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia Previously Treated With VenetoclaxActive, not recruitingPhase 1City of Hope Medical CenterNCT05222984Written as NavitoclaxHow we know
- Navitoclax in Relapsed or Refractory High-Risk Myelodysplastic SyndromeCompletedPhase 1Thomas Jefferson UniversityNCT05564650Written as NavitoclaxHow we know
- Study of Oral Navitoclax Tablet In Combination With Oral Ruxolitinib Tablet When Compared With Oral Ruxolitinib Tablet To Assess Change In Spleen Volume In Adult Participants With MyelofibrosisCompletedPhase 3AbbVieNCT04472598Written as NavitoclaxHow we know
- Combination Navitoclax, Venetoclax and Decitabine for Advanced Myeloid NeoplasmsActive, not recruitingPhase 1Jacqueline Garcia, MDNCT05455294Written as NavitoclaxHow we know
- A Study Evaluating Tolerability and Efficacy of Navitoclax Alone or in Combination With Ruxolitinib in Participants With MyelofibrosisCompletedPhase 2AbbVieNCT03222609Written as NavitoclaxHow we know
- Study of Oral Navitoclax Tablet in Combination With Oral Ruxolitinib Tablet Versus Best Available Therapy to Assess Change in Spleen Volume in Adult Participants With Relapsed/Refractory MyelofibrosisActive, not recruitingPhase 3AbbVieNCT04468984Written as NavitoclaxHow we know
- Safety Study of ABT-263 in Combination With Rituximab in Lymphoid CancersCompletedPhase 1AbbVieNCT00788684Written as ABT-263How we know
- A Study Evaluating Safety and Tolerability, and Pharmacokinetics of Navitoclax Monotherapy and in Combination With Ruxolitinib in Participants With Myeloproliferative NeoplasmActive, not recruitingPhase 1AbbVieNCT04041050Written as NavitoclaxHow we know
- Navitoclax and Sorafenib Tosylate in Treating Patients With Relapsed or Refractory Solid TumorsCompletedPhase 1National Cancer Institute (NCI)NCT02143401Written as NavitoclaxHow we know
- Combination of Olaparib and Navitoclax in Women with HGSC and TNBCActive, not recruitingPhase 1Sunnybrook Health Sciences CentreNCT05358639Written as NavitoclaxHow we know
- Osimertinib and Navitoclax in Treating Patients With EGFR-Positive Previously Treated Advanced or Metastatic Non-small Cell Lung CancerCompletedPhase 1National Cancer Institute (NCI)NCT02520778Written as NavitoclaxHow we know
- HEM-iSMART-A: Decitabine / Venetoclax and Navitoclax in Pediatric Patients With Relapsed or Refractory Hematological MalignanciesWithdrawnPhase 1/2Princess Maxima Center for Pediatric OncologyNCT05740449Written as NavitoclaxHow we know
- Adding Targeted Drugs to Usual Chemotherapy for Adults With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia (T-ALL) and T-Cell Lymphoblastic Lymphoma (T-LBL)WithdrawnPhase 2National Cancer Institute (NCI)NCT06210750Written as NavitoclaxHow we know
- Navitoclax and Vistusertib in Treating Patients With Relapsed Small Cell Lung Cancer and Other Solid TumorsTerminatedPhase 1/2National Cancer Institute (NCI)NCT03366103Written as NavitoclaxHow we know
- A Study of ABT-263 in Participants With Relapsed or Refractory Chronic Lymphocytic LeukemiaCompletedPhase 1/2AbbVieNCT00481091Written as ABT-263How we know
- A Study of Venetoclax in Combination With Navitoclax and Chemotherapy in Subjects With Relapsed/Refractory Acute Lymphoblastic Leukemia or Relapsed/Refractory Lymphoblastic LymphomaCompletedPhase 1AbbVieNCT03181126Written as NavitoclaxHow we know
- A Study of ABT-263 in Subjects With Relapsed or Refractory Lymphoid MalignanciesCompletedPhase 1/2AbbVie (prior sponsor, Abbott)NCT00406809Written as ABT-263How we know
See all 37 studies that test navitoclax →
Given beside what is tested · 6 — navitoclax is usual care or a partner of the new treatment
- Testing the Addition of Navitoclax to the Combination of Dabrafenib and Trametinib in People Who Have BRAF Mutant MelanomaActive, not recruitingPhase 1/2National Cancer Institute (NCI)NCT01989585Written as NavitoclaxHow we know
- Safety and Tolerability Study of Oral ABBV-744 Tablet Alone or in Combination With Oral Ruxolitinib Tablet or Oral Navitoclax Tablet in Adult Participants With MyelofibrosisActive, not recruitingPhase 1AbbVieNCT04454658Written as NavitoclaxHow we know
- Venetoclax-Navitoclax With Cladribine-based Salvage Therapy in Patients With Relapsed/Refractory Acute Myeloid LeukemiaWithdrawnPhase 1Medical College of WisconsinNCT06007911Written as Navitoclax Dose Level -1How we know
- Genetically Risk-Stratified Venetoclax, Ibrutinib, Rituximab (± Navitoclax) in Relapsed/Refractory Mantle Cell LymphomaActive, not recruitingPhase 2Peter MacCallum Cancer Centre, AustraliaNCT05864742Written as NavitoclaxHow we know
- Safety and Tolerability Study of Mivebresib Tablet Alone or in Combination With Ruxolitinib Tablet or Navitoclax Tablet in Adult Participants With MyelofibrosisTerminatedPhase 1AbbVieNCT04480086Written as NavitoclaxHow we know
- Study of ABT-263 When Administered in Combination With Either Fludarabine/Cyclophosphamide/Rituximab or Bendamustine/Rituximab in Relapsed or Refractory Chronic Lymphocytic LeukemiaCompletedPhase 1AbbVie (prior sponsor, Abbott)NCT00868413Written as ABT-263How we know
Codes
What other systems call navitoclax · ClinicalTrials.gg INT005266
- MeSH (NLM) C528561navitoclaxConfirmed ClinicalTrials.gov, NLM, Wikidata
- UNII (FDA) XKJ5VVK2WDNAVITOCLAXConfirmed FDA, NLM, Wikidata
- Wikidata Q18002993navitoclaxConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C64776NavitoclaxOne source FDA
- DrugBank DB12340One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C528561 | navitoclax | Confirmed ClinicalTrials.gov, NLM, Wikidata |
| UNII (FDA) | XKJ5VVK2WD | NAVITOCLAX | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q18002993 | navitoclax | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C64776 | Navitoclax | One source FDA |
| DrugBank | DB12340 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.